Abstract
Background Myocardial dysfunction is a recognized toxicity of anthracycline (A) and herceptin (H) chemotherapy. Whilst there is much current focus on the incidence and magnitude of myocardial dysfunction following the A/H regimen, whether these changes are mediated by reversible or irreversible myocardial injury remains unknown. We sought to determine rates of persistent LV dysfunction at 12 months (as defined by left ventricular ejection fraction (LVEF) decrease by 10% or below lower limits of normal) following A/H and explore the mechanism of myocardial dysfunction using advance cardiac imaging.
Highlights
Myocardial dysfunction is a recognized toxicity of anthracycline (A) and herceptin (H) chemotherapy
LVEF decreased from 72.4 ± 6.4 to 64.8 ± 6.4 at 12 months; p value < 0.001
global longitudinal strain (GLS) showed no significant change at 1 month, decreased in absolute magnitude from -21.2 ± 3% baseline to -19.2 ± 1.8% (p ≤ 0.001) at 3 months
Summary
And late left ventricular effects of breast cancer chemotherapy: a prospective multi-centre study using advanced cardiac imaging. Suchi Grover1,2*, Carmine DePasquale, Govindarajan Srinivasan, Darryl P Leong, Adhiraj Chakrabarty, Kerry A Cheong, Rohit Joshi, Amy Penhall, Majo Joseph, Bogda Koczwara, Joseph Selvanayagam. From 16th Annual SCMR Scientific Sessions San Francisco, CA, USA. From 16th Annual SCMR Scientific Sessions San Francisco, CA, USA. 31 January - 3 February 2013
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.